UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
Specialized Disclosure Report
ABIOMED, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware |
|
001-09585 |
|
04-2743260 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
22 Cherry Hill Drive, Danvers, Massachusetts |
|
01923 |
(Address of principal executive offices) |
|
(Zip Code) |
Todd A. Trapp
978-646-1400
(Name and telephone number, including area code, of the person to contact in connection with this report)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
☒ |
Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2021. |
Section 1 — Conflict Minerals Disclosure
Item 1.01 |
Conflict Minerals Disclosure and Report |
Conflict Minerals Disclosure
This Form SD of ABIOMED, Inc. (the “Company”) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2021 to December 31, 2021.
A copy of our Conflict Minerals Report is filed herewith as Exhibit 1.01 hereto and is publicly available at: www.abiomed.com.
Information appearing on www.abiomed.com is not a part of, and is not incorporated by reference into, this Form SD.
Item 1.02 |
Exhibit |
A Conflict Minerals Report required by Item 1.01 covering the period January 1, 2021 to December 31, 2021 has been filed as Exhibit 1.01 to this Form SD.
Section 2 — Exhibits
Item 2.01 |
Exhibits |
The following exhibit is filed as part of this report.
Exhibit Number |
|
Description |
1.01 |
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: May 20, 2022 |
|
ABIOMED, INC. (Registrant) |
||
|
|
|
||
|
|
By: |
|
/s/ Todd A. Trapp |
|
|
|
|
|
|
|
|
|
Todd A. Trapp Vice President, Chief Financial Officer
|
|
|
|
|
|
Exhibit 1.01
ABIOMED, Inc.
Conflict Minerals Report
For The Year Ended December 31, 2021
This Conflict Minerals Report (this “Report”) of ABIOMED, Inc. (the “Company”) has been prepared as provided for in Rule 13p-1 and Form SD (the “Conflict Minerals Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2021 to December 31, 2021.
The Conflict Minerals Rule requires public companies to make certain disclosures if the products they manufacture or contract to manufacture contain “Conflict Minerals” that are “necessary to the functionality or production” of those products. As used herein and consistent with the Conflict Minerals Rule, Conflict Minerals are defined as cassiterite, columbite-tantalite, wolframite and gold, including their derivatives, which are limited to tin, tantalum and tungsten (collectively, “3TG minerals”). Also as used herein and consistent with the Conflict Minerals Rule, the “Covered Countries” are the Democratic Republic of the Congo and its adjoining countries.
Description of the Company’s Products Covered by this Report
The Company’s products, which are referred to in this Report collectively as the “Covered Products,” are mechanical circulatory support devices used in the care of heart failure patients. The Company’s Covered Products are manufactured using integrated systems incorporating materials and assemblies provided by multiple suppliers.
As required by the Conflict Minerals Rule, the Company has conducted a good faith reasonable country of origin inquiry (“RCOI”) regarding the 3TG minerals included in its products during the reporting period from January 1, 2021 to December 31, 2021 to determine whether any such minerals originated or may have originated in a Covered Country and were not from recycled or scrap sources. Where applicable, the Company conducted additional due diligence regarding the sources of the 3TG minerals. The results of the Company’s good faith RCOI regarding the 3TG minerals, as well as its additional due diligence regarding the sources of such minerals, are contained in this Report. The Company’s Form SD and this Report are publicly available at www.abiomed.com. The content on any web site referred to in this Report is not incorporated by reference into this Report unless expressly noted.
Description of Product Scoping, RCOI and Due Diligence Measures
The Company does not purchase 3TG minerals directly from mines, smelters or refiners, and there are many third parties in the supply chain between the ultimate manufacture of the Covered Products and the original sources of the 3TG minerals. The Company must therefore rely on its suppliers to provide information regarding the origin of the 3TG minerals that are included in the Covered Products. Accordingly, and consistent with the Organization for Economic Co-Operation and Development (“OECD”) Due Diligence for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas (Third Edition), the Company conducted an inquiry into its supply chain to determine whether any of the 3TG minerals utilized in its Covered Products originated in the Covered Countries.
The review consisted of the following steps:
The Company continues to enhance its due diligence measures to try to further mitigate the risk that the 3TG minerals in Covered Products supported armed groups in the Covered Countries. These steps include, among others, continuing to engage with its suppliers, reminding them of the Company’s obligation under the Conflict Minerals Rule and the Company’s expectation that all covered suppliers cooperate with its diligence efforts.